trial

Single Ascending Dose Study of RBP-7000

NCTId NCT02768649
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 45 (actual)
Sponsored by Indivior Inc.
Primary completion 2012-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2011-04
Primary completion
2012-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RBP-7000Risperidone

Sponsors

Indivior Inc.Lead Sponsor

Sites

1 total
Willingboro, United States

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE1
Primary Completion Date
2012-02
Status
COMPLETED
relationships
The graph out of here
drug
RBP-7000
drug
Risperidone
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication